Helen Louise Collins
CIK 1701247 · CHIEF MEDICAL OFFICER · last filed 2026-07-21
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$1.73M
Companies
6
Total Filings
54
Lifetime Open-Market Net
-$5.37M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ELVN | CHIEF MEDICAL OFFICER | 25,063 | $53.76 | $1.35M | -$263.4K | 1 | 2026-07-21 |
| IMRA | CHIEF MEDICAL OFFICER | 26,133 | $14.49 | $378.7K | -$5.11M | 14 | 2026-06-22 |
| KURA | Director | — | $9.31 | — | $0 | 6 | 2026-06-04 |
| IO Biotech, Inc. (IOBT) Delisted | Director | — | $0.05 | — | $0 | 3 | 2025-06-06 |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | EVP and Chief Medical Officer | 69,547 | $38.00 | $2.64M | $0 | 9 | 2021-04-19 |
| FIVE PRIME THERAPEUTICS, INC. (XLRN) Delisted | EVP and Chief Medical Officer | 44,298 | $178.75 | $7.92M | $0 | 14 | 2019-09-04 |
Recent Filings · Page 3 of 6
54 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-06-07 | KURA | Grant (A) | — | $0 | EDGAR |
| 2024-06-07 | IO Biotech, Inc. (IOBT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-04-15 | IMRA | Mixed | — | -$451.9K | EDGAR |
| 2024-04-11 | ELVN | Notice (144) | −20,000 | -$396.4K | EDGAR |
| 2024-02-15 | IMRA | Grant (A) | — | $0 | EDGAR |
| 2023-11-17 | IO Biotech, Inc. (IOBT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-02 | KURA | Grant (A) | — | $0 | EDGAR |
| 2023-04-06 | IMRA | Grant (A) | — | $0 | EDGAR |
| 2023-02-27 | IMRA | Grant (A) | — | $0 | EDGAR |
| 2022-06-23 | KURA | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.